1.705
3.45%
-0.035
Lexicon Pharmaceuticals Inc 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Sees Significant Decline in Short Interest - MarketBeat
MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Sees Significant Decline in Short Interest - Defense World
Defense World
How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? - Yahoo Movies Canada
Yahoo Movies Canada
Lexicon resubmits FDA application for sotagliflozin for type 1 diabetes - MSN
MSN
Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday - Quantisnow
Quantisnow
Lexicon resubmits FDA application for sotagliflozin for type 1 diabetes - MSN
MSN
Lexicon Pharmaceuticals Inc (LXRX) Stock: A Year of Highs and Lows - The InvestChronicle
The InvestChronicle
You might want to take a look at Lexicon Pharmaceuticals Inc (LXRX) now – Sete News - SETE News
SETE News
Surging Earnings Estimates Signal Good News for Lexicon (LXRX) - Yahoo New Zealand News
Yahoo New Zealand News
A stock that deserves closer examination: Lexicon Pharmaceuticals Inc (LXRX) – US Post News - US Post News
US Post News
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Reiterated by HC Wainwright - MarketBeat
MarketBeat
HC Wainwright Reiterates “Buy” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - Defense World
Defense World
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
BRIEF—Lexicon Pharmaceuticals resubmits sotagliflozin NDA | The Pharmaletter - The Pharma Letter
The Pharma Letter
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks Investment Research
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes - ForexTV.com
ForexTV.com
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes - StockTitan
StockTitan
BRIEF—Lexicon Pharmaceuticals resubmits sotagliflozin NDA | The Pharmaletter - The Pharma Letter
The Pharma Letter
Views of Wall Street's Leading Experts on Lexicon Pharmaceuticals Inc – Sete News - SETE News
SETE News
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to Post Q2 2024 Earnings of ($0.18) Per Share, HC Wainwright ... - Defense World
Defense World
How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? - Yahoo Movies Canada
Yahoo Movies Canada
Closing Figures: Lexicon Pharmaceuticals Inc (LXRX)'s Positive Finish at 1.75, Up 1.74 – DWinneX - The Dwinnex
The Dwinnex
Brokers Set Expectations for Lexicon Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:LXRX) - MarketBeat
MarketBeat
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association - ForexTV.com
ForexTV.com
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed ... - StockTitan
StockTitan
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed ... - StockTitan
StockTitan
Brokers Set Expectations for Lexicon Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:LXRX) - MarketBeat
MarketBeat
Sanofi to pay Lexicon $260 million for terminated partnership - Yahoo Movies UK
Yahoo Movies UK
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasted to Post FY2024 Earnings of ($0.65) Per Share - MarketBeat
MarketBeat
LXRX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
The InvestChronicle
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal ... - StockTitan
StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Earn FY2024 Earnings of ($0.65) Per Share - Defense World
Defense World
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal ... - StockTitan
StockTitan
Lexicon Pharmaceuticals Inc (LXRX) did well last session? – US Post News - US Post News
US Post News
Lexicon Pharmaceuticals (NASDAQ:LXRX) Research Coverage Started at HC Wainwright - MarketBeat
MarketBeat
HC Wainwright Initiates Coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) - Defense World
Defense World
H.C. Wainwright starts Lexicon Pharmaceuticals stock at 'Buy', sees strong growth potential - Investing.com South Africa
Investing.com South Africa
H.C. Wainwright starts Lexicon Pharmaceuticals stock at 'Buy', sees strong growth potential By Investing.com - Investing.com
Investing.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Research Coverage Started at HC Wainwright - MarketBeat
MarketBeat
How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? - Yahoo Movies Canada
Yahoo Movies Canada
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association - ForexTV.com
ForexTV.com
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored ... - StockTitan
StockTitan
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored ... - StockTitan
StockTitan
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last? - Yahoo Canada Finance
Yahoo Canada Finance
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored ... - StockTitan
StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by BVF Inc. IL - Defense World
Defense World
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Purchased by BVF Inc. IL - MarketBeat
MarketBeat
Leerink Partners initates Lexicon Pharmaceuticals Inc (LXRX) stock to an Outperform – Knox Daily - Knox Daily
Knox Daily
Financial Snapshot: Analyzing Lexicon Pharmaceuticals Inc (LXRX)'s Key Ratio Metrics – DWinneX - The Dwinnex
The Dwinnex
A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) – Sete News - SETE News
SETE News
자본화:
|
볼륨(24시간):